Equity Analysis /

IbnSina Pharma: Annual performance back to norm, base effect shapes sequential performance

  • Retail segment grown on ASP; ISPH outperforms market

  • Revenue growth held back by slow retail growth, despite solid wholesale performance

  • G&A expenses and IFRS16 implementation hold back bottom line, A weak base effect led the sequential surge


Tellimer | Start Following

Start following your markets today

Follow your key analysts, markets and more so they appear here in your Watchlist - allowing you to keep an eye on the latest updates.